Pharmaceutical Research 2010-09-01

Inhalable microparticles as carriers for pulmonary delivery of thymopentin-loaded solid lipid nanoparticles.

Yan-Zhen Li, Xun Sun, Tao Gong, Jie Liu, Jiao Zuo, Zhi-Rong Zhang

Index: Pharm. Res. 27(9) , 1977-86, (2010)

Full Text: HTML

Abstract

Microparticles containing solid lipid nanoparticles (SLNs) are receiving increased attention as carriers for the lung delivery of the SLNs. Thus, we aim to prepare the hybrid microparticles and thoroughly evaluate their feasibility for the pulmonary drug delivery.The microparticles were prepared by co-spray-drying the thymopentin (TP5)-loaded SLNs with bulking agents. Thereafter, we systematically estimated the potential of the microparticles as the carriers for the pulmonary delivery of the SLNs, including the investigations of their characteristics, aerodynamic properties, pharmacokinetics and pharmacodynamics.The spherical and hollow microparticles presented a size of 4.1 +/- 0.1 microm and a low tap density of 0.175 +/- 0.02 g/cm(3). In addition, the microparticles showed a high aerosolization efficiency (emitted dose of 98.0% +/- 1.23% and respirable fraction of 51.07% +/- 1.21%). Furthermore, the SLNs could be easily recovered from the microparticles without essential changes on their characteristics and the drug release behavior. The pharmacokinetic and pharmacodynamic studies suggested that, compared to i.v. TP5 solution, the bioavailability and therapeutic efficacy of TP5 were remarkably strengthened after the pulmonary administration of the microparticles.Taken together, we believe the microparticles were suitable for inhalation and possessed an ample potential for the pulmonary delivery of the SLNs.


Related Compounds

  • Thymopentin

Related Articles:

Stability and aerosolization of pressurized metered dose inhalers containing thymopentin nanoparticles produced using a bottom-up process.

2012-05-10

[Int. J. Pharm. 427(2) , 385-92, (2012)]

Separation and purification of thymopentin with molecular imprinting membrane by solid phase extraction disks.

2015-01-01

[J. Pharm. Biomed. Anal. 102 , 137-43, (2014)]

[Vulvar lesions caused by Papillomavirus (HPV): effectiveness of thymopentin (Syntomoduline). First results and experiences].

1991-01-01

[Minerva Ginecol. 43(1-2) , 53-6, (1991)]

Peptides and polypeptides as modulators of the immune response: thymopentin--an example with unknown mode of action.

1999-06-01

[Pharm. Acta Helv. 73(6) , 265-73, (1999)]

Immunomodulation with thymopentin: in vitro studies.

1989-01-01

[Med. Oncol. Tumor Pharmacother. 6(1) , 19-23, (1989)]

More Articles...